Charles Jones, Ph.D. – CEO, Co-founder

Prior to joining Abcombi Biosciences, Dr. Jones developed the core IP used to found the company during his Ph.D. studies at the University at Buffalo. Previously, Dr. Jones was employed by Advanced Liquid Logics (acquired by Illumina) as a member of the Point of Care team. He has also been active in the Western New York and national business venture and development activities including the selective NSF I-Corps program. Dr. Jones has published over 20 peer-reviewed articles in scientific journals that include Nature Biotechnology, Proceedings of the National Academy of Sciences, and Science Advances. Dr. Jones has degrees in Chemical Engineering (B.S. and Ph.D.) and Biochemistry (B.S.) and is currently enrolled in the MBA program at the University of Chicago's Booth School of Business.



Andrew Hill, Ph.D.  – CSO, Co-founder

Prior to joining Abcombi Biosciences, Mr. Hill conducted research in synthetic biology at the University of Texas at Austin. Specifically, Mr. Hill is an expert in designing metabolic networks for the production of industrially-relevant chemicals and drugs. Mr. Hill received a B.S. degree in Chemical and Biomolecular Engineering from North Carolina State University, and has recently transfered to the University at Buffalo to complete his Ph.D. in Chemical and Biological Engineering. 



Marie Beitelshees - Associate of Research and Strategy

Prior to joining Abcombi Biosciences, Ms. Beitelshees conducted research on pneumococcal vaccine design at the University at Buffalo, where she is currently pursuing a PhD in Chemical and Biological Engineering. Ms. Beitelshees also has a degree in Chemical Engineering (B.S.) from Montana State University.